Golden Biotechnology Co., Ltd of Taiwan is a drug development oriented biotechnology company that was founded in 2002. With the world’s leading drug screening platform GBC is able to rapidly screen the effectiveness of components along with the help of domestic and foreign top medical scientists to create the best team of both worlds.

2017

Golden Biotechnology Corp. Receives US Patent Approval for Treating Neurodegenerative Diseases.
Golden Biotechnology Corp. Acquires Japanese Patent for Treating Arteriosclerosis Disease.
Golden Biotechnology Corp. Completed Registration in ClinicalTrials of NIH for its New Drug Clinical Trial in treatment of Pancreatic Cancer.
Golden Biotechnology Corp. Awarded USP GMP Audit Certificate and Meets GMP Requirement in ICH-GMP for API.
Golden Biotechnology works with Queensland QUT on Alzheimer’s cure.
FDA Grants a Clinical Trial of Antroquinonol in combination with standard Nab-paclitaxel plus Gemcitabine as First-Line Therapy for Pancreatic Cancer.

2016

Golden Biotechnology Corp.’s New Drug Hocena for treating of cancer and hyperlipidemia won National Innovation Award in Taiwan.

Golden Biotechnology Corp. won the Advance Queensland – Johnson & Johnson Innovation QuickFire Challenge Award with potential treatment for Alzheimer’s disease.

2015

Golden Biotechnology Corp. was granted 3 orphan drug designations for the treatment of pancreatic cancer , acute myeloid leukemia (AML) and liver cancer by US FDA.

2014

Antroquinonol®( trademark Hocena ®) on Non-Small-Cell Lung Cancer (NSCLC) Phase II clinical trial starts in US and Taiwan.

2013

Antroquinonol® acquired US patent「Methods and compositions for treating cancer metastasis」,patent No. US 8,648,117 B2,with a total of 9 US patents.

Antroquinonol®( trademark Hocena ®) passed Phase I clinical trial, and has been approved of Phase II clinical trial on Non-Small-Cell Lung Cancer (NSCLC) by US FDA.

2012

Winner of Top Enterprise 2012 and Winner of Top 10 Outstanding Manager by OEMA, ROC.

2011

Golden Biotechnology Japan was established; Golden Biotechnology Corporation(Beijing) was established.

2010

Launched Rasle, concentrated Antrodia camphorata. Antroquinonol® had been used in clinical trials by FDA IND administrated plan. Passed the human clinical trials of new drugs in Taiwan and United States

2009

Acquired three certified patents (United States, Korea and New Zealand). Completed the pre-clinical testing, and applied for clinical trials to constantly expanding into new drug development

2008

Completed toxicological studies (in vitro & in vivo). Acquired 9 certified patents (United States, Taiwan, Singapore, England and Germany). Awarded the National Health Food Certificate issued by Department of Health, Taiwan. Awarded the 2008 National Biotechnology and Medical Care Quality Award and the Silver Prize, Taiwan

2007

The first company obtained the functional food license from the Department of Health in Taiwan (License #00124) for liver protection on our product – GDAC. Awarded the 2007 Symbol of National Quality in Health Food Category by Institute for Biotechnology and Medicine Industry, Taiwan. Awarded the 2007 National innovation award in the Innovative Technology Category for Biotechnology and Medicine Industry, Taiwan

2006

Successfully utilized the patented solid state fermentation process to cultivate Antrodia camphorata. The major component Antroquinonol® was first identified in the extract of Antrodia camphorata and produced as a natural compound for cancer adjuvent therapies

2005

Identified key bioactive compounds from Antrodia camphorata

2004

Extracted and analyzed the nutritional ingredients from native herbs. Constructed a database and explored the unique components. Cultivated the fresh body of Antrodia camphorata

2003

Successfully installed three unique screening platforms for prostate cancer, breast cancer and cardiovascular disease. Established three databanks – Fermentation Databank, Natural Product Collection Databank, and Chemical Databank

2002

Golden Biotechnology was founded in September